Treatment Start to Full Effect of Immunotherapies for MS – Medscape

Izanne Roos1,2, Emmanuelle Leray3, Federico Frascoli4, Romain Casey58, J. William L. Brown9, Dana Horakova10, Eva K. Havrdova10, Maria Trojano11, Francesco Patti12,13, Guillermo Izquierdo14, Sara Eichau14, Marco Onofrj15, Alessandra Lugaresi16,17, Alexandre Prat18, Marc Girard18, Pierre Grammond19, Patrizia Sola20, Diana Ferraro20, Serkan Ozakbas21, Roberto Bergamaschi22, Maria Jos S23, Elisabetta Cartechini24, Cavit Boz25, Franco Granella26,27, Raymond Hupperts28, Murat Terzi29, Jeannette Lechner-Scott30,31, Daniele Spitaleri32, Vincent Van Pesch33, Aysun Soysal34, Javier Olascoaga35, Julie Prevost36, Eduardo Aguera-Morales37, Mark Slee38, Tunde Csepany39, Recai Turkoglu40, Youssef Sidhom41, Riadh Gouider41, Bart Van Wijmeersch42, Pamela McCombe43,44, Richard Macdonell45,46, Alasdair Coles9, Charles B. Malpas1,2, Helmut Butzkueven4749, Sandra Vukusic57 and Tomas Kalincik1,2, on behalf of the MSBase* and OFSEP investigators*

1 CORe, Department of Medicine, University of Melbourne, Melbourne, 3050, Australia 2 Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, 3050, Australia 3 Rennes University, EHESP, REPERES (Pharmaco-epidemiology and Health services research) - EA 7449, Rennes, France 4 Faculty of Science, Engineering and Technology, School of Science, Department of Mathematics, Swinburne University of Technology, Melbourne, 3122, Australia 5 University of Lyon, Claude Bernard University Lyon 1, F-69000 Lyon, France 6 Hospices Civils de Lyon, Service de Neurologie, sclrose en plaques, pathologies de la myline et neuro-inflammation, F-69677 Bron, France 7 Observatoire Franais de la Sclrose en Plaques, Lyon Neuroscience Research Centre, INSERM 1028 et CNRS UMR 5292, F-69003 Lyon, France 8 EUGENE DEVIC EDMUS Foundation against multiple sclerosis, state-approved foundation, F-69677 Bron, France 9 Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0QQ, UK 10 Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, 12808, Czech Republic 11 Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, 70122, Italy 12 GF Ingrassia Department, University of Catania, Catania, 95123, Italy 13 Policlinico G Rodolico, 95123, Catania, Italy 14 Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain 15 Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, 66100 Chieti, Italy 16 IRCCS Istituto delle Scienze Neurologiche di Bologna, UOSI Riabilitazione Sclerosi Multipla, Bologna, 40139, Italy 17 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy 18 CHUM MS Center and Universite de Montreal, Montreal, H2L 4M1, Canada 19 CISSS Chaudire-Appalache, Lvis, Levis, G6X 0A1, Canada 20 Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, 41100, Italy 21 Dokuz Eylul University, Konak/Izmir, 35220, Turkey 22 IRCCS Mondino Foundation, Pavia, 27100, Italy 23 Centro Hospitalar Universitrio de So Joo and Universidade Fernando Pessoa, 4249004 Porto, Portugal 24 UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, 62100, Italy 25 KTU Medical Faculty Farabi Hospital, Karadeniz Technical University, Trabzon, 61080, Turkey 26 Department of Medicine and Surgery, University of Parma, Parma, 43126, Italy 27 Department of General Medicine, Parma University Hospital, Parma, 43126, Italy 28 Zuyderland Ziekenhuis, Sittard, Sittard, 6131 BK, The Netherlands 29 Medical Faculty, 19 Mayis University, Kurupelit, Samsun, 55160, Turkey 30 School of Medicine and Public Health, University Newcastle, 2308, Australia 31 Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, 2305, Australia 32 Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Contrada Amoretta, Avellino, 83100, Italy 33 Cliniques universitaires Saint-Luc, Brussels, 1200 BXL, Belgium 34 Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, 34142, Turkey 35 Instituto de Investigacin Sanitaria Biodonostia, Hospital Universitario Donostia, San San Sebastin, Spain, 20014, Spain 36 CSSS Saint-Jrme, Saint-Jrme, QC J7Z 0H6, Canada 37 Hospital Universitario Reina Sofia Cordoba (IMIBIC), 14004 Cordoba, Spain 38 Flinders University, Adelaide, 5042, Australia 39 Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, 4032, Hungary 40 Haydarpasa Numune Training and Research Hospital, Selimiye Mahallesi, Istanbul, 34668, Turkey 41 Department of Neurology, Razi Hospital, 2010, Tunis, Manouba, Tunisia 42 Rehabilitation and MS-Centre Overpelt and Hasselt University, Hasselt, 3900, Belgium 43 University of Queensland, St Lucia, 4072, Australia 44 Royal Brisbane and Women's Hospital, Herston, 4029, Australia 45 Department of Neurology, Austin Health, Heidlberg, 3084, Australia 46 Faculty of Medicine and Dental Health Sciences, University of Melbourne, Melbourne, 3050, Australia 47 Central Clinical School, Monash University, Melbourne, 3004, Australia 48 Department of Neurology, The Alfred Hospital, Melbourne, 3004, Australia 49 Department of Neurology, Box Hill Hospital, Monash University, Melbourne, 3128, Australia

Correspondence to Tomas Kalincik CORe, Department of Medicine, University of Melbourne, 300 Grattan St, Melbourne, 3050, Australia E-mail: tomas.kalincik@unimelb.edu.au

*Appendix 1.

Competing interests The authors have received research support, support to attend conferences, speaker honoraria and fees for participation at advisory boards from Actelion, Almirall, Bayer-Schering, Biogen, BioCSL, Celgene, EMD, Geneuro, Medday, Merck, Myalin, Novartis, Roche, Sanofi-Genzyme, Teva, WebMD Global outside the submitted work.

Visit link:
Treatment Start to Full Effect of Immunotherapies for MS - Medscape